paclitaxel (QR 207) / Qrono - LARVOL DELTA

FYA 24: Paclitaxel: Lessons Learned From the Past and Future Perspectives with Dr Schneider (Radcliffe Group) - "In this video, Dr Peter Schneider...outlines the big picture of paclitaxel therapies, including lessons learnt from the controversy and the future of paclitaxel devices."

Video

Paclitaxel-Coated Balloons for Femoropopliteal Artery Disease Treatment in French Patients: A Longitudinal Observational Study (submitted at JACC interv) (JET 2024) - No abstract available.

Comparison between collagen versus sutured based vascular devices for arterial closure following PAD revascularization: a RCT (JET 2024) - No abstract available.

AGENT of Change for ISR Treatment: Why Paclitaxel - Monday, April 1, 2024, 7:00 am-8:00 am.

Live event

Dr. @riess_md closes out #MaTOS23 with an overview of thymic malignancies. Immunotherapy active but toxic in thymic carcinoma (too toxic for thymoma). Great results with carboplatin + paclitaxel + ramucirumab in the RELEVENT trial by Dr. @ClaudiaProto83

First-Line NALIRIFOX Demonstrates Survival Advantage Over Standard Gemcitabine/Paclitaxel in Metastatic PDAC (OncLive) - "Eileen M. O'Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward."

Interview

Next Steps for Paclitaxel: Experts Provide Views and Opinions at the 49th Annual VEITHsymposium (YouTube) - https://www.youtube.com/watch?v=VEDLr0gWO6g

Video

From Clinical Trials to Real-World Practice, Experts Examine the Best Options for TNBC (Cancer Network) - "Rugo...examined the use of neoadjuvant therapeutics for early disease and potential adjuvant therapy-sparing regimens."

Media quote

Randomized Phase II of Pacliaxel/Carboplatin +/- Eltanexor in Platinum Sensitive Ovarian, Tubal, Peritoneal Carcinoma patients that have progressed on PARP inhibitor maintenance (NRG Winter 2023) - No abstract available.

Paclitaxel Safety Concerns Wane as Hope Emerges for Newer PAD Devices (TCTMD) - "'We have a lot of reassuring data about safety that has occurred outside of the original pivotal trials in [the Katsanos] meta-analysis,' Secemsky told TCTMD. Indeed, SAFE-PAD adds to other long-term safety data from SWEDEPAD and VOYAGER PAD. These along with updated meta-analyses done by VIVA have 'quieted' the conversation, Secemsky added, and shifted the emphasis back to the critical importance of the devices for patients with PAD who need revascularization. Four years on, the harm signal, he concluded, is 'now crossing the line of null.'"

Media quote

TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years (TCTMD) - "Secemsky, who has led several studies trying to get to the bottom of the paclitaxel safety story, including multiple real-world Medicare analyses that found nothing to support the long-term mortality signal, told TCTMD that while he personally has no lingering concerns about paclitaxel use in peripheral interventions, some operators remain unconvinced and would likely find a low-dose version of a DCB appealing."

The current role of paclitaxel DCB in PCI - EuroPCR 2022 (YouTube) - "Thanks to the different interventions of this session, understand the role of paclitaxel DCB in modern era interventional cardiology, the differences, and advantages versus DES, the role of blended therapies in CLS, and learn how to correctly prepare the lesion and obtain the best from this technology on the long term. With...Antonio Micari."

Video

With New Options for the Treatment of Cervical Cancer, Considering Individual Patient Characteristics is Essential (Pharmacy Times) - "Similar to the COVID-19 pandemic, Monk said it is essential to educate patients on the importance of prevention and testing for human papillomavirus (HPV) because it can cause cervical cancer. 'If COVID has taught us anything, it's that if you don't get vaccinated, you might die,' Monk said in the presentation. 'And that's the same with HPV. Monk noted that the death rate from cervical cancer has dropped by more than 50% since 1975. Between 2007 and 2016, in fact, the death rate decreased by about 1% each year in women 50 years of age and older but remained stable in women younger than 50 years of age....'Obviously we want patients to live longer, it's about survival,' Westin said. 'But this is good survival.'"

Media quote • Novel Coronavirus Disease

Adjuvant Pembrolizumab Plus Chemoradiotherapy Combo Will Be Investigated in High-Risk Endometrial Cancer (Cancer Network) - P3, N=990; KEYNOTE-B21 (NCT04634877); Sponsor: Merck Sharp & Dohme Corp; "Investigators with begin assessing the use of adjuvant pembrolizumab (Keytruda) plus chemotherapy or chemoradiotherapy in patients with newly diagnosed, high-risk early endometrial cancer on the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial (NCT04634877). Details of the trial in progress were presented in a poster by author Brian Slomovitz, MD, during The Society of Gynecologic Oncology (SGO) 2022 Annual Meeting on Women's Cancer. Investigators of the ongoing study are evaluating pembrolizumab vs placebo administered in combination with adjuvant chemotherapy carboplatin plus paclitaxel with or without radiation therapy in patients with newly diagnosed high-risk endometrial cancer after surgery with curative intent....noted that the individual efficacy results for the 2 approaches led to the rationale for the trial."

Media quote

My Treatment Approach: Endometrial Carcinoma - Episode 4: Dose Reduction in Endometrial Carcinoma Treatment (OncLive) - "Bradley Monk, MD, FACOG, FACS: I follow the recipe. Just because you reduce the dose, doesn't mean you started at the wrong dose. Patients get dose reduced on our PARP inhibitors in ovarian cancer, paclitaxel, all this. If the patient is protocol-like healthy and has good end-organ function then I'd treat her like the protocol....David O'Malley, MD: They'll go fairly quickly, and then suddenly they're in trouble. You're right. With the short half-life, it will get better all the time. But I like them to have that prescription in their hand."

Video

Use of Inhibitor Combination Based on MSI Status in Endometrial Cancer (Targeted Oncology) - "P3 | N= NA| KEYNOTE-775 (NCT03517449)| Sponsor: Eisai Inc.| "Bhavana Pothuri, MD...discusses the results of the KEYNOTE-775 trial (NCT03517449) in patients with advanced endometrial cancer in relation to microsatellite instability (MSI) status. According to Pothuri, the randomized phase 3 KEYNOTE-775 trial of pembrolizumab (Keytruda) and lenvatinib (Lenvima) showed superior progression-free survival (PFS) and overall survival (OS) versus doxorubicin or paclitaxel in patients who had been previously treated with platinum-based chemotherapy. However, the combination of pembrolizumab and lenvatinib was approved for patients without MSI-high (MSI-H) status or a mismatch repair deficiency (dMMR) based on the study results."

Video

Frontline Maintenance in Ovarian Cancer - EP. 4: Case Scenario: Stage 3A High-Grade Epithelial Ovarian Cancer (OncLive) - "...Robert W. Holloway, MD, review the case of a 57-year-old woman with stage IIIA high-grade epithelial ovarian cancer....One point you brought up was in frontline therapy, making a decision whether you're going to use bevacizumab. In this case, I wonder about the decision because they didn't describe a lot of bulky disease. With the inguinal nodes making it extra peritoneal, kind of a stage IV patient, I didn't know if that's why we did it....The problem is that it's cross studied with 2 different populations, higher risk and niraparib. But because you got the patient here into remission, it's rational to use bevacizumab with carbo-Taxol [carboplatin, paclitaxel] to continue that in your maintenance phase and add the olaparib because she's HRD positive."

Video

Pembrolizumab shows durable activity in subset of women with endometrial cancer (Healio) - "'These findings suggest a long-term benefit to patients. Even the potential for curative intent is now possible in patients with recurrent or metastatic uterine cancer' David M. O'Malley, MD...said in a press release. 'By targeting this damaged pathway with this targeted drug, we can reset the cellular mechanisms and allow the immune system to reactivate and attack the cancer cells,' O'Malley said."

Media quote

Cervical Cancer Treatment Paradigm Is Bolstered With Newly Approved Therapies (OncLive) - "'It's exciting to see this flurry of activity in cervical cancer. We have tripled the survival [rate], which is heartwarming and incredible for our patients. This field is going to continue to evolve,' Bhavana Pothuri, MD, said. First-Line Metastatic Cervical Cancer Treatment Managing metastatic cervical cancer in the firstline setting includes treating women with de novo stage IVB or recurrent cancer after chemotherapy or radiation, Bradley Monk, MD, FACOG, FACS, said. 'We don't count chemotherapy or radiation as a line of therapy,' he said....'The OS hasn't been accomplished yet,' Thaker said....'In 2 years, I think the algorithm for how we treat patients with recurrent cervical cancer will be completely different. It's the dawn of a new era. It's incredibly exciting,' Huh said."

Media quote

A 64-Year-Old Woman With Advanced Endometrial Carcinoma - Episode 4: Advanced Endometrial Carcinoma Treatment Selection (Targeted Oncology) - "Robert L. Coleman, MD, FACOG, FACS: This patient fell into the typical algorithm. She was treated with adjuvant radiation for her high risk for local recurrence. She had a distant recurrence. She was treated with combination chemotherapy, paclitaxel and carboplatin, and then recurred again after a relatively short time. She was given lenvatinib and pembrolizumab, which aligns very well with the treatment algorithm for patients who have microsatellite-stable tumors. This would have been right along the lines of what we would have hoped for. Fortunately, because of the accelerated approval mechanism, we had access to this drug well before its regular approval in July. But this patient did fall in line with the treatment algorithm that we would have ordinarily undertaken with the availability of that combination."

Video

Active Clinical Trials of Interest in Endometrial Cancer Explore Novel Up-Front Approaches (OncLive) - "Bradley R. Corr, MD, discusses practice-changing developments and active clinical trials that are being done in endometrial cancer. Comparing the use of novel immunotherapeutic approaches with standard chemotherapy in the frontline setting represents a key focus of research in the endometrial cancer paradigm...[Several] active clinical trials are [being done] in endometrial cancer, [and they really give us] a sense of where treatment is [headed]. In [this disease], a big focus is onimmunotherapy, and specifically checkpoint blockade. Several clinical trials are evaluating immunotherapy in either combination with chemotherapy or as single-agent therapy."

Media quote

A 64-Year-Old Woman With Advanced Endometrial Carcinoma - Episode 7: Advanced Endometrial Carcinoma: Treatment Pipeline (Targeted Oncology) - "Robert L. Coleman, MD, FACOG, FACS: The relationship of the molecular biology of endometrial cancer and the opportunities based on available compounds, which continues to grow every day, is very optimistic and exciting. We have several trials that are focused largely on the combination or addition of immune checkpoint inhibitors to a mostly chemotherapy backbone for patients who have either recurrent or primarily metastatic disease.One of these trials, LEAP-001, is trying to take on combination paclitaxel-carboplatin in that line of therapy for patients with advanced-stage or first recurrent endometrial cancer. Pembrolizumab and lenvatinib are being compared with paclitaxel and carboplatin. In the patients with deficient MMR [mismatch repair], we're looking at single-agent pembrolizumab against chemotherapy as well. We're using or leveraging the biology to move the field along."

Video

Paclitaxel-Carboplatin Established as Standard of Care for Uterine Carcinosarcoma— Median OS and PFS improved versus paclitaxel-ifosfamide (MedPageToday) - "'Found to be noninferior to IP [ifosfamide-paclitaxel], yet easier to administer in the outpatient setting and harboring a significantly safer toxicity profile, CP [carboplatin-paclitaxel] has become a new standard for patients with UCS,'...and Daniela Matei, MD..."

Media quote

A 64-Year-Old Woman With Advanced Endometrial Carcinoma - Episode 1: Case Overview: 64-Year-Old Woman With Advanced Endometrial Carcinoma (Targeted Oncology) - "Robert L. Coleman, MD, FACOG, FACS: This is a 64-year-old postmenopausal woman who presented with abnormal uterine bleeding for about 2 months. She has 2 grown children, underwent menopause at age 57, and has no known family history of cancer. Her past medical history is significant for a body mass index [BMI] of 32. She has hypertension that’s well controlled with medication. Her physical examination is mostly notable for a large uterus, and she has some right lower quadrant abdominal tenderness on palpation."

Video

Vascular online training LINC 2021 using sirolimus in CLTI seems to be better (YouTube) - "Vascular online training great presentation on the use of sirolimus coated balloon in BTK segments and the comparison of paclitaxel coated balloons."

Video